Reviewing GE HealthCare Technologies (NASDAQ:GEHC) & AxoGen (NASDAQ:AXGN)

AxoGen (NASDAQ:AXGN) and GE HealthCare Technologies (NASDAQ:GEHC) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

Insider & Institutional Ownership

80.3% of AxoGen shares are held by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are held by institutional investors. 2.4% of AxoGen shares are held by company insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares AxoGen and GE HealthCare Technologies”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21 million	8.60	-$15.70 million	($0.68)	-53.00
GE HealthCare Technologies	$20.62 billion	1.42	$2.08 billion	$4.36	14.83

GE HealthCare Technologies has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than GE HealthCare Technologies, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

AxoGen has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, GE HealthCare Technologies has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for AxoGen and GE HealthCare Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1	2	11	0	2.71
GE HealthCare Technologies	0	10	11	1	2.59

AxoGen presently has a consensus target price of $51.70, indicating a potential upside of 43.45%. GE HealthCare Technologies has a consensus target price of $78.52, indicating a potential upside of 21.42%. Given AxoGen’s stronger consensus rating and higher probable upside, research analysts plainly believe AxoGen is more favorable than GE HealthCare Technologies.

Profitability

This table compares AxoGen and GE HealthCare Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.36%	-8.90%	-6.47%
GE HealthCare Technologies	9.33%	20.12%	5.74%

Summary

GE HealthCare Technologies beats AxoGen on 9 of the 14 factors compared between the two stocks.

About AxoGen

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

About GE HealthCare Technologies

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women’s health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women’s health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.